MARKET

BOLD

BOLD

BOUNDLESS BIO INC
NASDAQ
1.160
+0.070
+6.42%
After Hours: 1.160 0 0.00% 16:00 02/06 EST
OPEN
1.140
PREV CLOSE
1.090
HIGH
1.190
LOW
1.125
VOLUME
285.02K
TURNOVER
--
52 WEEK HIGH
2.540
52 WEEK LOW
0.9612
MARKET CAP
25.97M
P/E (TTM)
-0.0722
1D
5D
1M
3M
1Y
5Y
1D
Boundless Bio CEO to Join Guggenheim Emerging Outlook Biotech Summit Fireside Chat
Reuters · 3d ago
Is Boundless Bio (NASDAQ:BOLD) In A Good Position To Invest In Growth?
Simply Wall St · 4d ago
Weekly Report: what happened at BOLD last week (0126-0130)?
Weekly Report · 6d ago
Weekly Report: what happened at BOLD last week (0119-0123)?
Weekly Report · 01/26 09:11
Boundless Bio announces FDA accepted IND application of BBI-940
TipRanks · 01/20 12:16
Boundless ceases enrollment of Phase 1/2 Potentiate trial of BBI-355, BBI-825
TipRanks · 01/20 12:15
Boundless Bio Unveils ecDNA-Directed Cancer Therapy Strategy in New Presentation
Reuters · 01/20 12:09
BOUNDLESS BIO INC: PORTFOLIO PRIORITIZATION, INCLUDING DISCONTINUATION OF POTENTIATE TRIAL, EXTENDS OPERATING RUNWAY INTO H2 2028
Reuters · 01/20 12:05
More
About BOLD
Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that address the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target.

Webull offers Boundless Bio Inc stock information, including NASDAQ: BOLD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BOLD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BOLD stock methods without spending real money on the virtual paper trading platform.